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Abstract
Introduction. Doctors of almost all specialties have to deal with the problem of pain and its relief. According to the 
literature, almost 30 million people daily take analgesics from the group of non-opioid analgesics, but in more than half 
of them 4-6 hours after taking the medication, the severity of pain is unchanged.
Objective. to search for the most active molecules potential selective inhibitors of the TRPA1 ion channel with further 
investigation of their pharmacodynamic effects, toxicological safety, pharmacokinetic parameters and organ distribu-
tion, as well as to assess their impact on the psychoemotional state, general locomotor activity levels and anxiety in 
laboratory animals.
Materials and methods. According to the results of in vitro tests, the most active molecule under code ZC02-0012 was 
selected from the pool of candidates. Further its analgesic activity was evaluated using an acetic acid-induced writhing 
test and a hot plate test; its anti-inflammatory activity was studied in the acute exudative paw edema model; in the open 
field and elevated plus-maze tests the influence of ZC02-0012 on the general locomotor activity levels and the anxiety 
of the laboratory animals was studied. The pharmacokinetic parameters and organ distribution of the substance ZC02-
0012 were studied using a liquid chromatograph with an operating pressure range of 0-60 mPa (Thermo Scientific 
Dionex UltiMate 3000).
Results and discussion. According to the results of in vitro tests, it was found that IC50 of the TRPA1 selective in-
hibitor under laboratory code ZC02-0012 was 91.3 nmol. The preclinical studies showed that ZC02-0012 possessed 
pronounced analgesic and anti-inflammatory activities and absence of the influence on the behavior and anxiety of 
the laboratory animals. Absolute bioavailability of ZC02-0012 in rabbits was 47%, while ZC02-0012 was intensely 
distributed into organs and tissues with a high level of blood circulation. The highest content of ZC02-0012 is typical 
of liver, kidneys and lungs, the lowest – for muscle tissue. Most of the substance is undergone rapid biotransformation 
and excreted as metabolites.
Copyright Beskhmelnitsyna EA et al. This is an open access article distributed under the terms of  the Creative Commons Attribution License (CC-BY 4.0), which 
permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
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Introduction
Doctors of almost all specialties have to deal with the 
problem of pain and its relief. Pain is the cause of health 
encounter in 90% of cases worldwide (Mamchur and 
Kovalenko 2016). According to the results of the Euro-
pean epidemiological study of the prevalence of men-
tal disorders, which was attended by 1659 respondents 
younger than 75 years, it was found that for the study 
group the problem of pain was relevant (55.2%), excee-
ding the level of depression and anxiety (11,6%) (Briggs 
et al. 2016, König et al. 2010). Surveys of patients in 
German hospitals showed that more than 80% (n=438) 
of them suffered from pain during the 3 months prior to 
hospitalization, and in more than 60% the pain syndrome 
was the cause of hospitalization (Kotova 2013). Accor-
ding to some reports, 19% of the European population 
suffer from the chronic pain (Leadley et al. 2014). In the 
USA, by the number of patients, chronic pain syndrome 
outnumbers even such common pathological conditions 
as diabetes mellitus, cardiovascular diseases and cancer 
(Gatchel 2014). At the same time, pain is not only a nega-
tive feeling, but also reduces the quality of life of the pa-
tient, negatively affecting family and interpersonal relati-
onships, leading to a decrease in and even loss of ability 
to work and is associated with huge economic problems 
for health care.
However, despite all modern research in the field of 
pharmacology and pharmacotherapy of the pain syndro-
me, guidelines and practical recommendations designed 
for doctors on the principles of adequate pain relief, 
patients are often left without proper therapy (Cascorbi 
2015). According to the literature, almost 30 million peo-
ple daily take analgesics from the group of non-opioid 
analgesics (Garland 2014, Mamchur and Kovalenko 
2016), but in more than half of them, 4-6 hours after ta-
king the medication, the severity of pain remains unchan-
ged (Moore et al. 2015).
Despite the current recommendations for the treatment 
of the pain syndrome, indicating the need for pathogene-
tic therapy, most practitioners continue to prescribe non-
steroidal anti-inflammatory drugs (NSAIDs) even when 
there is no tissue damage or inflammation, although the 
optimal use of NSAIDs, opioid analgesics or a combinati-
on of drugs in patients with chronic pain is still the subject 
of research (Dhalla et al. 2012, Wehling 2014).
The mechanism of analgesic action of opioid (narcotic) 
analgesics is mainly due to the interaction with µ1-recep-
tors. However, not only analgesic effect of this group of 
drugs, but also a number of side effects, such as respira-
tory depression, nausea and vomiting, the development 
of euphoria, drug dependence, increased smooth muscle 
tone are realized through interaction with opioid receptors 
(Arbuh 2017).
NSAIDs are widely used for pain relief at all stages of 
medical care. This group of drugs is especially popular in 
the treatment of diseases of the musculoskeletal system 
and joints, which are based on inflammation. Realization 
of drugs of this group is carried out mainly through phar-
macies (about 90% of sales), and over-the-counter sale 
makes them easily accessible and increases the risk of 
complications and side effects of pharmacotherapy (Zhu-
rakhovskaya et al. 2014).
Therefore, today it is actually to search for new mo-
lecules that can selectively block the “targets”, directly 
detecting pain stimuli and inflammatory mediators. One 
of these targets is a TRPA1 ion channel.
Objective
To search for the most active molecules candidates for 
selective inhibitors of the TRPA1 ion channel with further 
investigation of their pharmacodynamic effects, toxi-
cological safety, pharmacokinetic parameters and organ 
distribution, as well as to assess their impact on the psy-
choemotional state, general locomotor activity levels and 
anxiety in laboratory animals.
To achieve this objective, it is necessary to solve the 
following research tasks:
1. To select molecules candidates for selective inhibitors 
of the TRPA1 ion channel according to the selectivity 
criteria in in vitro tests.
2. To carry out the dosage selection of the most active 
and safe compounds from the group of substituted py-
razinopyrimidinones based on the results of the study 
of LD50, and calculation of therapeutic doses.
3. To investigate the analgesic activity of the TRPA1 se-
lective inhibitor under laboratory code ZC02-0012 in 
intragastric and intramuscular administration using the 
hot plate test.
4. To investigate the analgesic activity of the TRPA1 se-
lective inhibitor under laboratory code ZC02-0012 in 
intragastric and intramuscular administration using the 
acetic acid-induced writhing test.
5. To investigate the anti-inflammatory activity of the 
TRPA1 selective inhibitor under laboratory code ZC02-
0012 in intragastric and intramuscular administration 
using the acute exudative paw edema model.
6. To study the influence of the TRPA1 selective inhibitor 
under laboratory code ZC02-0012 on emotional and 
behavioral activity, the general locomotor activity le-
vels and the anxiety in intragastric and intramuscular 
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administration using the open field and elevated plus 
maze tests.
7. To conduct preclinical studies of pharmacokinetics, 
organ distribution and metabolism of the TRPA1 selec-
tive inhibitor under laboratory code ZC02-0012.
Materials and methods
The experiments were performed at the Research Institute 
of the Pharmacology of the Living Systems of Belgorod 
State National Research University and ChemRar High-
Tech Center. All the experiments were approved by the 
Ethical Committee of Belgorod State National Research 
University. Vivisection was carried out in accordance 
with the ethical principles of handling laboratory animals 
“The European Convention for the Protection of Vertebral 
Animals Used for Experimental and Other Scientific Pur-
poses. CETS No. 170”.
Initially, the most promising candidates for selective 
ion channel antagonists, which showed the percentage 
of inhibition of the cellular calcium response above 
50% - 3*SDmaximum and own agonistic activity less 
than 10% + 3*SDminimum, were selected from the 1.5 
million library of small organic molecules at the dis-
posal of ChemRar High-Tech Center using the high 
throughput molecular screening. Then their mecha-
nism of action and specific activity were confirmed in 
cells with superexpression of TRPA1 ion channel. For 
hits, the IC50 value was determined in GraphPad Prism 
(GraphPad Software, Inc., San Diego, CA). To con-
struct the concentration dependence, the equation was 
chosen (Formula 1):
 (1)
The test substances were synthesized by ChemRar 
High-Tech Center, under the leadership of General Direc-
tor Dmitriy V. Kravchenko. The structures of the synthe-
sized potential molecules are given in Table 1.
According to the results of in vitro tests, a molecule un-
der laboratory code ZC02-0012 was selected as the most 
active for further studies in laboratory animals.
The study of a general toxical action was performed in 
white mice of both sexes weighing 20±2 g. Animals were 
administered the prepared solution of the active phar-
maceutical substance ZС02-0012 using a metal stomach 
tube with a smooth olive on the end at the maximum for 
mice and their body weight volume of 0.5 ml, four-time 
administration during the day with 1 hour intervals. The 
maximum possible dose for the administration of the test 
substance was 5000 mg/kg.
The toxic effect of the substance was evaluated by the ge-
neral condition of the animals and their survival, LD50. Sur-
vivors and dead animals were calculated within 3 days after 
the priming of the substance, followed by keeping watch 
over the surviving animals for two weeks after the priming.
The study of the analgesic activity of the selective in-
hibitor of the TRPA1 ion channel, active pharmaceutical 
substance under code ZC02-0012 was performed in two 
tests: hot plate and acetic acid-induced writhing test.
A. Hot plate Test
The experiments were performed in white laboratory mice of 
either sex weighing 22 to 28 g. To simulate the pain syndro-
me, the animals were placed on a preheated 55°C hot plate 
(Hot-Plate LE7406, Panlab Harvard Apparatus, Spain), and 
the time in seconds was recorded until the pain behavior (lic-
king and pulling up the legs, bouncing, squeaking) started. 
Then all the animals were divided into groups, depending on 
the administered substance and administration way:
Group I – control, the intragastric administration of PEG-
400 (n=15);
Group II – the intragastric administration of the selective 
inhibitor of TRPA1 ion channel at a dose of 1 mg/kg 
(n=15);
Group III – the intragastric administration of the selective 
inhibitor of TRPA1 ion channel at a dose of 3 mg/kg 
(n=15);
Group IV – the intragastric administration of the selective 
inhibitor of TRPA1 ion channel at a dose of 9 mg/kg 
(n=15);
Group V – the intragastric administration of the reference 
drug Ketorolac (Dr. Reddy’s laboratories Ltd, India) at 
a dose of 3.48 mg/kg (n=15);
Group VI – control, the intramuscular administration of 
PEG-400 (n=15);
Group VII – the intramuscular administration of the se-
lective inhibitor of TRPA1 ion channel at a dose of 1 
mg/kg (n=15);
Group VIII – the intramuscular administration of the se-
lective inhibitor of TRPA1 ion channel at a dose of 3 
mg/kg (n=15);
Group IX – the intramuscular administration of the selec-
tive inhibitor of TRPA1 ion channel at a dose of 9 mg/
kg (n=15);
Group X – the intramuscular administration of the refe-
rence drug Ketorolac (Dr. Reddy’s laboratories Ltd, 
India) at a dose of 3.48 mg/kg (n=15).
At intervals of 30, 60, 90 and 120 minutes after admi-
nistration of the test substances, the experimental animals 
were re-placed on a plate heated to 55ºC, and the time in 
seconds until the pain behavior was recorded. The analge-
sic action was evaluated by increasing the exposure time 
of the animals on the hot plate.
B. Acetic acid-induced writhing test
The experiments were performed in white inbred rats of both 
sexes weighing 200-220 g. The animals were administered 
by the test substances intramuscularly or intragastrrically.
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Table 1. Chemical Structures of the Test Substances.
Substances Structures
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Group I – control, the intragastric administration of poly-
ethylene glycol 400 (PEG-400);
Group II – the intragastric administration of the selective 
inhibitor of TRPA1 ion channel at a dose of 0.46 mg/
kg (n=15);
Group III – the intragastric administration of the selective 
inhibitor of TRPA1 ion channel at a dose of 1.38 mg/
kg (n=15);
Group IV – the intragastric administration of the selective 
inhibitor of TRPA1 ion channel at a dose of 4.15 mg/
kg (n=15);
Group V – the intragastric administration of the reference 
drug Ketorolac (Dr. Reddy’s laboratories Ltd, India) at 
a dose of 1.6 mg/kg (n=15);
Group VI – control, the intramuscular administration of 
PEG-400;
Group VII – the intramuscular administration of the se-
lective inhibitor of TRPA1 ion channel at a dose of 0.46 
mg/kg (n=15);
Group VIII – the intramuscular administration of the se-
lective inhibitor of TRPA1 ion channel at a dose of 1.38 
mg/kg (n=15);
Group IX – the intramuscular administration of the selec-
tive inhibitor of TRPA1 ion channel at a dose of 4.15 
mg/kg (n=15);
Group X – the intramuscular administration of the refe-
rence drug Ketorolac (Dr. Reddy’s laboratories Ltd, 
India) at a dose of 1.6 mg/kg (n=15).
Thirty minutes after intramuscular administration and 
1 hour after intragastric administration of the test sub-
stances to simulate the pain syndrome, the experimental 
animals was injected intraperitoneally with 0.75% solu-
tion of acetic acid at the rate of 1 ml per 100 g weight of 
the animal. A count of the number of “writhes” started 15 
min later and was carried out for 30 min. Writhes are the 
characteristic movements of animals, including contracti-
ons of abdominal muscles, alternating with their relaxa-
tion, the stretching of hind paws and bowing of the back 
(Mironov et al. 2012). Analgesic effect was estimated by a 
reduced number of writhes compared to those in the con-
trol group and calculated by Formula 2:
Eanalg = %100×
−
ê
îê
Ñ
ÑÑ
 (2)
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where: С
о is the number of “writhes” after test substances 
administration and С
к is the number of “writhes” before 
test substances administration.
The experiments to study the anti-inflammatory ac-
tivity were performed in white laboratory mice of both 
sexes weighing 22-28 g. The anti-inflammatory effect was 
evaluated in a model of acute aseptic inflammation of the 
mice paw by a degree of inhibiting an increase in paw 
edema on the background of drugs administration compa-
red with the control group of the untreated animals. The 
experimental animals were administered intragastrically 
or intramuscularly with the studied substances.
Group I – control, the intragastric administration of PEG-
400 (n=15);
Group II –the intragastric administration of the selective 
inhibitor of TRPA1 ion channel at a dose of 1 mg/kg 
(n=15);
Group III – the intragastric administration of the selective 
inhibitor of TRPA1 ion channel at a dose of 3 mg/kg 
(n=15);
Group IV – the intragastric administration of the selective 
inhibitor of TRPA1 ion channel at a dose of 9 mg/kg 
(n=15);
Group V – the intragastric administration of the referen-
ce drug Diclofenac sodium (Chemopharm, Serbia) at a 
dose of 13.91 mg/kg (n=15);
Group VI – control, the intramuscular administration of 
PEG-400 (n=15);
Group VII – the intramuscular administration of the se-
lective inhibitor of TRPA1 ion channel at a dose of 1 
mg/kg (n=15);
Group VIII – the intramuscular administration of the se-
lective inhibitor of TRPA1 ion channel at a dose of 3 
mg/kg (n=15);
Group IX – the intramuscular administration of the selec-
tive inhibitor of TRPA1 ion channel at a dose of 9 mg/
kg (n=15);
Group X – the intramuscular administration of the refe-
rence drug Diclofenac sodium (Chemopharm, Serbia) 
at a dose of 13.91 mg/kg (n=15).
Exudative edema was caused 45 min after administrati-
on of the test substances by subplant injection into the right 
hind paw of mice with 0.02 ml of 2% formaldehyde soluti-
on. The mass of the paw was measured 4 hours (peak ede-
ma) after injection of a phlogistic, using electronic scales 
with an accuracy of 1 mg; the left paw of the same animal, 
which was injected with an equal volume of isotonic NaCl 
along with the phlogistic injection, was used as a control. 
The inhibitory effect was calculated by Formula 3:
ê
êing
M
MME
∆
×∆−∆
=
%100)( 0  (3)
where: Eing is the inhibitory effect, ΔM0 is the average 
weight gain of the edematous paw in the experimental 
group and ΔMê is the average weight gain of the edema-
tous paw in the control group.
The study of the behavioral reactions in the open field 
test was performed in white male inbred rats weighing 
200-220 g. Twenty-four hours before the study, the ani-
mals were randomized and organized into experimental 
groups; with each rat individually labled. The test sub-
stances were administered intragastrically or intramus-
cularly 1 hour before testing, and then the animals were 
placed into a quiet, poorly lit room. During this period, 
the regrouping of the animals, feeding, picking them up 
and other active manipulations were excluded.
All animals were divided into groups:
Group I – control, the intragastric administration of PEG-
400;
Group II – the intragastric administration of the selective 
inhibitor of TRPA1 ion channel at a dose of 0.46 mg/
kg (n=15);
Group III – the intragastric administration of the selective 
inhibitor of TRPA1 ion channel at a dose of 1.38 mg/
kg (n=15);
Group IV – the intragastric administration of the selective 
inhibitor of TRPA1 ion channel at a dose of 4.15 mg/
kg (n=15);
Group V – the intragastric administration of the reference 
drug Ketorolac (Dr. Reddy’s laboratories Ltd, India) at 
a dose of 1.6 mg/kg (n=15);
Group VI – control, the intramuscular administration of 
PEG-400;
Group VII – the intramuscular administration of the se-
lective inhibitor of TRPA1 ion channel at a dose of 0.46 
mg/kg (n=15);
Group VIII – the intramuscular administration of the se-
lective inhibitor of TRPA1 ion channel at a dose of 1.38 
mg/kg (n=15);
Group IX – the intramuscular administration of the selec-
tive inhibitor of TRPA1 ion channel at a dose of 4.15 
mg/kg (n=15);
Group X – the intramuscular administration of the refe-
rence drug Ketorolac (Dr. Reddy’s laboratories Ltd, 
India) at a dose of 1.6 mg/kg (n=15).
Registration of the general locomotor activity of the 
animals was performed in the open field box (Open Field 
LE800S, PanLab Harvard Apparatus, Spain) for 10 minu-
tes. The lighting was done by a 100 W lamp, suspended 
at a height of 1.5 m from the bottom of the arena. The 
animals were placed in the open field near the wall of the 
arena. A zero-group animal was placed in the arena and 
allowed to freely examine the box for 5 minutes immedi-
ately before testing the rats of the experimental and con-
trol groups to provide equal footing in terms of olfactory 
signal between the first and subsequent animals. After 
the ”zero” and each subsequent animal, the arena and the 
walls of the box were wiped with a moist rag. For the data 
analysis, we used the program Smart v.3.0.03. (Panlab 
Harvard Apparatus, Spain).
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For the convenience of processing and simplifying the 
presentation of the results, the values of the registered 
parameters were generalized (Shevkunova et al. 2013). 
The following behaviors were analyzed: horizontal loco-
motion by the distance traveled in the center and outer 
zone of the field, vertical locomotion by the number of 
rearing behaviors, the percentage of time spent in each 
zone, reflecting the general locomotor activity of the ani-
mals, as well as the number of defecations and the total 
duration of grooming, characterizing the emotional state 
of the animal.
The study of behavioral reactions in the elevated-plus 
maze test was performed in white male inbred rats weig-
hing 200-220 g. Twenty-four hours before the study, the 
animals were randomized and organized into experimen-
tal groups, with each rat individually labled, and then 
coops with the animals were transferred from the viva-
rium to the room where the experiment was conducted. 
The test substances were administered intragastrically or 
intramuscularly 1 hour before the test. All animals were 
divided into groups:
Group I – control, the intragastric administration of PEG-
400;
Group II – the intragastric administration of the selective 
inhibitor of TRPA1 ion channel at a dose of 0.46 mg/
kg (n=15);
Group III – the intragastric administration of the selective 
inhibitor of TRPA1 ion channel at a dose of 1.38 mg/
kg (n=15);
Group IV – the intragastric administration of the selective 
inhibitor of TRPA1 ion channel at a dose of 4.15 mg/
kg (n=15);
Group V – the intragastric administration of the reference 
drug Ketorolac (Dr. Reddy’s laboratories Ltd, India) at 
a dose of 1.6 mg/kg (n=15);
Group VI – control, the intramuscular administration of 
PEG-400;
Group VII – the intramuscular administration of the se-
lective inhibitor of TRPA1 ion channel at a dose of 0.46 
mg/kg (n=15);
Group VIII – the intramuscular administration of the se-
lective inhibitor of TRPA1 ion channel at a dose of 1.38 
mg/kg (n=15);
Group IX – the intramuscular administration of the selec-
tive inhibitor of TRPA1 ion channel at a dose of 4.15 
mg/kg (n=15);
Group X – the intramuscular administration of the refe-
rence drug Ketorolac (Dr. Reddy’s laboratories Ltd, 
India) at a dose of 1.6 mg/kg (n=15).
Registration of the animals’ activity was carried out in 
the elevated-plus maze test LE840 (PanLab Harvard Ap-
paratus, Spain) for 5 minutes. The animals were placed 
in the center of the maze, with the nose to open arm. It 
is assumed that the animal will seek to explore a new 
environment, struggling with the fear of open space and 
height. A zero-group animal was placed in the arena and 
allowed to freely examine the box for 5 minutes immedi-
ately before testing the rats of the experimental and con-
trol groups to provide equal footing in terms of olfactory 
signal between the first and subsequent animals. After the 
”zero” and each subsequent animal, the arena and walls of 
the box were wiped with a moist rag. For the data analy-
sis, we used the program Smart v.3.0.03 (Panlab Harvard 
Apparatus, Spain).
The following behaviors were analyzed: duration in 
open arms and closed arms, the number of open and clo-
sed arm entries, total duration of grooming, as well as the 
number of hanging from the open arms and the number 
of defecations.
To study the pharmacokinetics of the TRPA1 selective 
inhibitor under code ZC02-0012, 12 rabbits were pre-ca-
theterized into the right ear vein so that blood samples at 
all time points were taken from the same animals throug-
hout the experiment. Twelve hours before the start of the 
experiment, the animals were deprived of feed, having 
free access to water. On the third day after catheterization, 
the test substance was administered.
Intravenously, the test substance was administered 
bolus to 6 rabbits in the ear vein at a dose of 10 mg/
kg in the form of a solution 10 mg/ml in propylene gly-
col. Blood was sampled through a catheter in a volume 
of 0.3 ml into polypropylene tubes containing 20 µl of 
5% EDTA prior to the administration, and then 10, 30, 
60, 90, 120, 180, 240 and 360 minutes after the injecti-
on. Intragastrically, the substance was administered at a 
dose of 10 mg/kg through stomach tube in the form of 
a solution of 10 mg/ml in propylene glycol. Blood was 
sampled through a catheter in a volume of 0.2 ml into 
polypropylene tubes containing 20 µl of 5% EDTA prior 
to injection, and then 10, 30, 60, 90, 120, 180, 240 and 
360 minutes after the injection. Blood plasma was sepa-
rated by centrifugation at 5600 g for 10 min and stored 
at a temperature of 70°C.
The organ distribution of the test substance was stu-
died in 60 male rabbits after a single intravenous adminis-
tration of ZC02-0012 to the animals at a dose of 10 mg/
kg. Whole blood, plasma, heart, spleen, muscles, liver, 
kidneys, brain and lungs were recovered before adminis-
tration and 5, 10, 30, 45, 60, 90, 120, 180, 240 minutes 
after administration of ZC02-0012.
The concentration of ZC02-0012 was determined 
using the previously developed HPLC method. In the 
specialized program Chromeleon 7, there were calcula-
ted the areas of the peaks of the analyzed substance and 
the internal standard, then the data was transferred to the 
Microsoft office Excel 2010, in which we calculated the 
equation of the calibration curve, statistically estimated 
deviations, graphically displayed the results. Concentra-
tions of substance ZC02-0012 in the studied objects were 
calculated in the program Microsoft office Excel 2010 by 
calibration curves.
The outliers in each time point were identified using 
Grubb’s test. If for any sample, the value of Z was greater 
than the critical value for the given number of measure-
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ments N, this sample was excluded from further calcula-
tions of pharmacokinetic parameters. Thus, for N=6, the 
critical value of Z was 1.89, so samples with Z>1.89 were 
considered as outliers (Bland 2000).
The concentration of ZC02-0012 in the homogenates 
of organs and tissues was also evaluated using the cali-
bration curves, then the concentration was recalculated in 
µg/g of tissue taking into account dilution (the final con-
centration was multiplied by two in accordance with the 
method of analysis).
The concentration of ZC02-0012 in excrement was 
detected by the same way, and the total amount of the 
substance in excrement was calculated in the observation 
intervals.
The main pharmacokinetic parameters were calculated 
in accordance with the guidelines for the preclinical stu-
dies of drugs under the editorship of A.N. Mironov, using 
Microsoft office Excel 2010. On the basis of experimen-
tally obtained data, there were calculated pharmacokine-
tic parameters and organ distribution.
The outliers in each time point were identified using 
Grubb’s test (Grubb’s Test for Detecting Outliers. URL: 
http://graphpad.com/quickcalcs/GrubbsExplain.cfm). 
There were calculated mean values and CV of the phar-
macokinetic parameters for 6 animals.
The results of the experiments were subjected to statis-
tical processing in accordance with modern concepts of 
mathematical processing of medical research data (Glantz 
1998, Kochetov et al. 2012), using IBM SPSS Statistics 
21 (USA).
The main objective of the statistical study was to com-
pare the indicators of ZC02-0012 groups with those of the 
control and reference drugs groups in order to solve the 
question of accepting a statistical hypothesis (H0/H1) in 
relation to a specific parameter. The hypothesis of signifi-
cant difference of values (HI) was accepted if its probabi-
lity was equal to or greater than 95%. In other cases, the 
null hypothesis (H0) was accepted.
The analysis of the quantitative parameters assumed, 
first of all, determination of their mean values (M), medi-
an (Me), first and third quartiles (Q1 and Q3) and standard 
errors. A normality of distribution of quantitative parame-
ters was assessed using Shapiro-Wilk W test. In order to 
accept a statistical hypothesis, Student’s t-test was calcu-
lated and compared with the critical value. In cases when 
the law of probability significantly differed from the nor-
mal one, the statistical hypothesis was accepted on the 
basis of the results of the nonparametric Kruskal-Wallis 
test. The Holm-Bonferroni correction for multiple testing 
was used to correct the effect of multiple comparison.
Results and discussion
The mechanism of action and specific activity of the new 
synthesized molecules were tested in cells with superex-
pression of the TRPA1 ion channel (Fig. 1). The obtained 
results confirm that the mechanism of action of all mo-
lecules is the antagonism of the TRPA1 ion channel. The 
activity of the substances is summarized in Table 2.
Thus, using in vitro screening, the specific activity 
of several synthesized substances was investigated. It is 
shown that all of them are antagonists of the TRPA1 ion 
channel. IC50 for all the substances was within the range 
of ~100-300 nmol. Since the substance under laboratory 
code ZC02-0012 showed the greatest activity (IC50 91.3 
nmol), this compound was chosen as the main candidate 
for preclinical studies.
The performed studies of acute toxicity showed that 
after four-time with an interval of 1 hour intragastric ad-
ministration to mice of active pharmaceutical substance 
ZC02-0012 in the largest for this species of animals and 
administration way dose of 5000 mg/kg, the deaths of 
animals were not observed within two weeks after acute 
priming.
Consequently, the results of keeping watch over the ex-
perimental animals in the intoxication period in the study 
of acute toxicity allow grading the investigated selective 
inhibitor of the TRPA1 ion channel ZC02-0012 to the V 
class of drugs (Hodge 1975).
In accordance with the experiment design, to study the 
analgesic effects in the hot plate test, the intact white labo-
ratory mice were placed on a plate heated to 55º in order 
to determine the pain threshold. Then divided into groups 
animals were administered the test substances, and the hot 
plate test was repeated 30, 60, 90 and 120 minutes after-
wards. The results are presented in Tables 3 and 4.
It was found that the test substance at a dose of 1 mg/kg 
in both intragastric and intramuscular administration does 
Figure 1. Concentration dependence of antagonistic activity 
on the concentration of the test substances. Each concentration 
point is an average of two repeats.
Table 2. Activity of the Test Substances to Suppress the Activity 
of the TRPA1 ion Channel.
Substance IC50, nmol
Ruthenium red 118.2
С276-1460 303.3
ZC02-0007 204.0
ZC02-0011 135.2
ZC02-0012 91.3
ZC02-0020 120.2
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not have an analgesic effect. At the same time, at the do-
ses of 3 mg/kg and 9 mg/kg, the selective inhibitor of the 
TRPA1 ion channel has an analgesic effect that exceeds 
that of the reference drug Ketorolac. In this case, both in-
tragastric and intramuscular administration of selective an-
tagonist ZC02-0012 retains its analgesic effect throughout 
the study period, up to 120 minutes, while for Ketorolac 
this effect is offset by the 90th minute with intramuscular 
administration and by the 120th minutes with intragastric 
administration. However, we did not find a significant dif-
ference in the intensity of the analgesic effect between the 
doses of 3 mg/kg and 9 mg/kg of the selective inhibitor of 
TRPA1, a substance under code ZC02-0012.
The acetic acid-induced writhing test is one of the 
most common in the evaluation of analgesic activity of 
non-narcotic analgesics. The pain reaction in this test is 
due to the activation of prostaglandin biosynthesis as a 
result of moderate short-term irritation of the peritoneum 
with a dilute solution of acetic acid.
Intraperitoneal injection of acetic acid solution to the 
control untreated rats causes a pain reaction in the form of 
writhes, expressed in the contraction of abdominal mus-
cles and stretching the hind paws. The number of writhes 
in such group within a 30-minute observation period is 
usually from 20 to 30.
In accordance with the experiment design, to study the 
analgesic effects in the acetic acid-induced writhing test, 
the males of inbred laboratory rats were administered the 
test substances in the studied doses, and then, 30 minutes 
after intramuscular administration and 60 minutes after 
intragastric administration there was performed intraperi-
toneal administration of 0.75% solution of acetic acid at 
the rate of 1 ml per 100 g of animals’ weight. The count of 
the number of writhes started 15 minutes after the injecti-
Table 4. Dynamics of Values of the Hot Plate Test in Intramuscular Administration of the Test Substances (M±m).
Substance Initial value 30 min 60 min 90 min 120 min
PEG-400 8.4+0.3 9.1+0.5 9.6+0.5 9.9+0.3 9.8+0.4
ZC02-0012 1 mg/kg 7.3+0.4 10.8+0.9 9.6+0.5 8.5+0.3 8.4+0.5
ZC02-0012 3 mg/kg 7.3+0.5 22.4+1.0** 17.3+0.8** 14.6+0.8** 12.4+0.8**
ZC02-0012 9 mg/kg 7.0+0.5 22.7+1.4** 17.7+1.1** 14.1+0.8** 11.5+0.8**
Ketorol3,48 mg/kg 7.2+0.5 17.6+0.9* 12.7+0.7* 9.8+0.6 8.3+0.6
Note: * - р<0.05 in comparison with PEG-400; ** - р<0.05 in comparison with Ketorol.
Table 3. Dynamics of Values of the Hot Plate Test in Intragastric Administration of the Test Substances (M±m).
Substance Initial value 30 min 60 min 90 min 120 min
PEG-400 7.7+0.4 8.0+0.6 8.2+0.4 8.9+0.5 8.8+0.4
ZC02-0012 1 mg/kg 7.6+0.4 9.2+0.4 10.9+0.6 10.5+0.5 9.6+0.5
ZC02-0012 3 mg/kg 7.2+0.5 15.1+0.9** 22.2+1.0** 16.4+0.8** 14.3+0.7**
ZC02-0012 9 mg/kg 7.5+0.5 15.4+0.7** 22.9+1.0** 17.7+1.3** 13.5+1.2**
Ketorol3,48 mg/kg 7.1+0.4 10.8+0.4* 16.6+0.6* 13.8+0.5* 10.8+0.4
Note: * - р<0.05 in comparison with PEG-400; ** - р<0.05 in comparison with Ketorol
Figure 2. Analgesic activity of the selective inhibitor of TRPA1 
ion channel, substance under code ZC02-0012, and the refer-
ence drug Ketorolac using the acetic acid-induced writhing test 
with intragastric administration.
Note: * – p<0.05 in comparison with PEG-400; ** – p<0.05 in 
comparison with Ketorol.
Figure 3. Analgesic activity of the selective inhibitor of TRPA1 
ion channel, substance under code ZC02-0012, and the refer-
ence drug Ketorolac using the acetic acid-induced writhing test 
with intramuscular administration.
Note: * – p<0.05 in comparison with PEG-400; ** – p<0.05 in 
comparison with Ketorolac.
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on of acetic acid and lasted for 30 minutes. The results are 
presented in Figures 2 and 3.
As the data presented in Figures 2 and 3 evidence, pre-
treatment with a selective inhibitor of TRPA1ion channel, 
substances under code ZC02-0012, at a dose of 0.46 mg/
kg has no analgesic effect either in the intragastric or in 
intramuscular administration. At the same time, the test 
substance ZC02-0012 at doses of 1.38 mg/kg and 4.15 
mg/kg and the reference drug Ketorolac, both in the intra-
gastric and intramuscular administration, cause a analge-
sia, manifested in a decreased number of writhes compa-
red to the control group, but in the selective antagonist of 
TRPA1ion channel, substance under code ZC02-0012, this 
effect is more pronounced than in Ketorolac. However, 
differences in analgesic effect between the doses of 1.38 
mg/kg and 4.15 mg/kg of substance ZC02-0012 in both 
administration ways were not statistically significant.
The results of the study of anti-inflammatory activity 
of ZC02-0012 showed that after a phlogistic was injected 
under the aponeurosis of the hind paw of the mice, all the 
experimental animals developed severe edema. The data 
obtained are presented in Tables 5 and 6.
From the tables above it can be seen that a single in-
tragastric and intramuscular administration of the selec-
tive inhibitor of TRPA1 ion channel, substance under code 
ZC02-0012 at a dose of 1 mg/kg does not have a statisti-
cally significant effect on the exudative phase of inflam-
mation, that is practically does not reduce the severity of 
edema of the hind paw in mice after the injection of 2% 
formaldehyde solution. At the same time, a single intra-
gastric and intramuscular administration of the substance 
under code ZC02-0012 at a dose of 3 and 9 mg/kg, as well 
as Diclofenac sodium at a dose of 13.91 mg/kg statistical-
ly significantly suppressed the severity of edema of the 
hind paw of the animal. However, there was no significant 
difference in the intensity of the inhibitory effect between 
the test substance under code ZC02-0012 and Diclofenac 
sodium and between the doses of 3 mg/kg and 9 mg/kg of 
the substance under code ZC02-0012. Thus, the selective 
inhibitor of the TRPA1ion channel, substance under code 
ZC02-0012, is comparable to the most active anti-inflam-
matory drug in the group of NSAIDs, Diclofenac sodium.
In the study of the general locomotor activity levels of 
animals in the open field test, the arena was divided into 
two zones – central and outer. It is known that placing an 
animal into a new environment contributes to the research 
behavior and emotions of fear, so in the open field test, 
during the first minutes of the study, the motor activity of 
animals is limited mainly to the outer zone and movement 
along the walls of the arena. The level of fear gradually de-
creases, and the animal begins to explore the central zone. 
In this regard, to study the effect of the test substances on 
the adaptive capabilities of the experimental animals, the 
distance traveled in each zone, as well as the time spent in 
each zone, was measured. The results of the study showed 
no significant differences in the horizontal activity of the 
Table 5. Anti-inflammatory Activity of the Selective Inhibitor of TRPA1 ion Channel, Substance Under Code ZC02-0012 and the 
Reference Drug Diclofenac sodium in Intragastric Administration in the model of Formalin Edema of the Mice Paw.
Substances and doses Weight of intact paw, 
M±m
Weight of edematous 
paw, M±m
Weight gain, g 
M±m
Weight gain, % 
M±m
Inhibitory effect, %
PEG-400 118.8+3.1 179.3+6 60.5+3.8 50.8+2.8 –
ZC02-0012 
1 mg/kg
114.1+3.6 169.5+4 55.3+2.6 49.3+2 2.73%
ZC02-0012 
3 mg/kg
120.3+1.6 142.3+2* 22+1.6* 18.4+1.4* 63.78%
ZC02-0012 
9 mg/kg
116.7+2.2 135+2.3* 18.3+1.0* 15.8+1.0* 68.78%
Diclofenac sodium 
13.91 mg/kg
122.3+1.9 141.5+2.5* 19.1+1.8* 15.7+1.5* 69.05%
Note: * – p<0.05 in comparison with PEG-400.
Table 6. Anti-inflammatory Activity of the Selective Inhibitor of TRPA1 ion Channel, Substance Under Code ZC02-0012 and the 
Reference Drug Diclofenac in Intramuscular Administration in the Formalin Edema Model in Mice Paw.
Substances and doses Weight of intact paw, 
M±m
Weight of edematous 
paw, M±m
Weight gain, g 
M±m
Weight gain, % 
M±m
Inhibitory effect, %
PEG-400 115.2+3.8 173.9+6.8 58.7+4.1 50.8+3.2 -
ZC02-0012 
1 mg/kg
114.3+3.7 169.6+4.8 57.7+4.0 49.1+3.3 3.5%
ZC02-0012 
3 mg/kg
123.1+1.9 144.4+2.6* 21.3+1.4* 17.3+1.1* 66%
ZC02-0012 
9 mg/kg
116.5+1.3 134+2* 17.5+1.7* 15+1.5* 70.4%
Diclofenac sodium 
13.91 mg/kg
123.2+2.4 141.9+2.6* 18.7+1.3* 15.3+1.2* 69.85%
Note: * – p<0.05 in comparison with PEG-400.
Beskhmelnitsyna EA et al.: Search and Evaluation of  Pharmacodynamic...58
animals in the experimental groups, compared with that in 
the control, both in intragastric and intramuscular adminis-
tration of the test substances (Tables 7, 8).
In addition to horizontal locomotor activity, the vertical 
motor activity of the experimental animals was also stu-
died by the number of rearing behaviors, the analysis of 
which showed no statistically significant differences bet-
ween the experimental and control groups, both in intra-
gastric and intramuscular administration of the substances 
(Tables 7, 8). To assess the emotional status of the animals 
in the open field test, the number of defecation acts and 
the total duration of grooming acts were evaluated. No 
significant differences of these criteria in comparison with 
the control were detected in any experimental group, neit-
her in intragastric nor in intramuscular administration of 
the test substances (Tables 7, 8).
When testing animals in the elevated plus maze test, a 
high level of locomotor activity was registered, the criteria 
of which did not differ significantly among different groups. 
All studied test parameters had no significant differences in 
the experimental and control groups (Tables 9, 10).
Thus, the results of the open field and elevated plus-ma-
ze tests showed that intragastric and intramuscular admi-
nistration of the selective inhibitor TRPA1, substance un-
der laboratory code ZC02-0012, at the doses of 0.46, 1.38 
and 4.15 mg/kg, as well as reference drug Ketorol (Dr. 
Reddy’s Laboratories Ltd., India) at a dose of 1.6 mg/kg 
does not have a negative effect on the behavioral reactions 
of animals, their level of anxiety and the general locomo-
tor activity levels.
The pharmacokinetic of ZC02-0012 was studied in 
blood plasma of rabbits in a single intravenous adminis-
tration at a dose of 10 mg/kg and intragastric administrati-
on at a dose of 10 mg/kg. The concentration of ZC02-0012 
in plasma is presented in Tables 11 and 12. The averaged 
pharmacokinetic curves (Figure 4) were constructed on 
the basis of the obtained data, and the main pharmacoki-
netic parameters were calculated.
Table 7. Results of the Open Field Test in Intragastric Administration of the Test Substances, Me [Q1; Q3].
Test criteria Administered substances and doses Р value
PEG-400 
n=15
ZC02-0012 0.46 
mg/kg 
n=15
ZC02-0012 1.38 
mg/kg 
n=15
ZC02-0012 4.15 
mg/kg 
n=15
Ketorol 1.6 mg/kg 
n=15
Horizontal locomotion in 
central zone (m)
1.67 
[0.54; 2.2]
1.14 
[0.03; 1.34]
0.86 
[0.08; 1.3]
1.23 
[0.18; 2.12]
1.24 
[0.0; 1.96]
0.603
Horizontal locomotion in 
outer zone (m)
64.21 
[50.19; 85.07]
64.1 
[47.34; 85.82]
59.79 
[44.87; 67.6]
55.41 
[39.35; 69.93]
74.8 
[49.99; 83.39]
0.297
Time spent in central 
zone (%)
0.33 
[0.19; 0.93]
0.15 
[0.02; 0.53]
1.11 
[0.12; 1.88]
0.92 
[0.5; 1.68]
1.1 
[0.02; 1.79]
0.088
Time spent in outer zone 
(%)
99.67 
[99.07; 99.81]
99.85 
[99.47; 99.98]
98.89 
[98.12; 99.88]
99.09 
[98.32; 99.5]
98.9 
[98.21; 99.98]
0.089
Rearing behavior 8 
[7; 10]
9 
[8; 13]
9 
[7; 13]
9 
[6; 12]
10 
[8; 11]
0.657
Total duration of 
grooming
17 
[14; 29]
26 
[19; 29]
27 
[16; 32]
24 
[18; 31]
21 
[16; 25]
0.417
Number of defecations 2 
[0; 3]
1 
[0; 2]
1 
[0; 2]
1 
[0; 3]
2 
[1; 3]
0.729
Table 8. Results of the Open Field Test in Intramuscular Administration of the Test Substances, Me [Q1; Q3].
Test criteria Administered substances and doses Р value
PEG-400 
n=15
ZC02-0012 0.46 
mg/kg 
n=15
ZC02-0012 1.38 
mg/kg 
n=15
ZC02-0012 4.15 
mg/kg 
n=15
Ketorol 1.6 mg/kg 
n=15
Horizontal locomotion in 
central zone (m)
1.03 
[0.44; 2.61]
1.3 
[0.74; 2.71]
1.81 
[0.0; 2.53]
1.58 
[0.74; 2.66]
1.51 
[1.08; 2.19]
0.955
Horizontal locomotion in 
outer zone (m)
60.93 
[58; 75.45]
55.18 
[48.06; 70.96]
81.12 
[63.56; 84.3]
59.87 
[49.04; 75.86]
67.85 
[52.17; 77.27]
0.165
Time spent in central 
zone (%)
1.11 
[0.1; 1.93]
0.84 
[0.15; 1.44]
0.64 
[0.0; 1.39]
0.84 
[0.13; 1.27]
1.29 
[0.32; 1.58]
0.619
Time spent in outer zone 
(%)
98.89 
[98.07; 99.9]
99.16 
[98.56; 99.89]
99.37 
[98.61; 100]
99.17 
[98.73; 99.87]
98.71 
[98.42; 99.69]
0.615
Rearing behavior 9 
[7; 10]
9 
[7; 10]
10 
[7; 13]
9 
[9; 11]
10 
[8; 12]
0.401
Total duration of 
grooming
25 
[18; 35]
25 
[20; 35]
27 
[20; 28]
22 
[12; 36]
28 
[21; 30]
0.946
Number of defecations 1 
[0; 3]
0 
[0; 2]
3 
[0; 3]
1 
[1; 2]
2 
[1; 2]
0.101
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Table 10. Results of the Elevated Plus-maze Test in Intramuscular Administration of the Test Substances, Me [Q1; Q3].
Test criteria Administered substances and doses Р value
PEG-400 
n=15
ZC02-0012 0,46 
mg/kg 
n=15
ZC02-0012 1,38 
mg/kg 
n=15
ZC02-0012 4,15 
mg/kg 
n=15
Ketorol 1,6 mg/kg 
n=15
Time spent in closed 
arms (sec)
255.64 
[238.05; 270.43]
261.96 
[237.22; 279.34]
251.71 
[231.77; 277.31]
244.69 
[236.69; 276.54]
259.33 
[242.28; 277.69]
0.873
Time spent in open 
arms(sec)
36.84 
[26.35; 53.93]
32.0 
[13.34; 54.2]
40.36 
[15.82; 60.66]
49.21 
[15.99; 59.17]
35.14 
[19.19; 51.22]
0.872
Number of open arm 
entries
2 
[2; 3]
2 
[1; 3]
2 
[1; 3]
2 
[1; 3]
2 
[1; 3]
0.521
Number of closed arm 
entries
4 
[2; 4]
3 
[3; 4]
4 
[3; 5]
3 
[3; 5]
3 
[2; 4]
0.503
Total duration of 
grooming
16.43 
[13.31; 21.89]
19.1 
[14.51; 21.39]
16.46 
[11.79; 20.26]
13.7 
[11.98; 21.89]
18.03 
[13.27; 20.23]
0.804
Number of hangings 
from the open arms
6 
[5; 7]
5 
[4; 7]
5 
[3; 6]
5 
[4; 7]
5 
[4; 6]
0.486
Number of defecations 1 
[1; 2]
2 
[1; 3]
2 
[0; 3]
1 
[0; 2]
2 
[0; 3]
0.692
The results obtained show that the maximum con-
centration of ZC02-0012 in blood plasma of rabbits was 
reached on average within 10 minutes after intragastric 
administration. The half-life was short (20.6 minutes). 
The mean absorption time (MAT) of ZC02-0012 was 4.2 
minutes. Absolute bioavailability fa (%) of ZC02-0012 in 
intragastric administration in rabbits was 47%.
The organ distribution of ZC02-0012 was studied af-
ter a single extravascular (intragastric) administration 
of the substance to rabbits at a dose of 10 mg/kg. The 
substance was well distributed to the organs. The maxi-
mum concentration in the studied organs was reached 
within 30 minutes after administration of ZC02-0012. 
The highest levels of ZC02-0012 were observed in liver 
(ft=216.9), kidney (ft=399.4) and lung (ft=332.0) tissues. 
The profiles of the distribution curves of ZC02-0012 
in the heart, brain and spleen are close. These organs 
are characterized by a close maximum concentration of 
ZC02-0012 and ft within 50-90. The lowest distribution 
of the substance ZC02-0012 was recorded for muscles, 
for which ft was 32. The average residence time of sub-
stance ZC02-0012 in tissues ranged from 90 to 140 mi-
nutes. The highest values are typical of kidneys, spleen 
and lungs.
Excretion of ZC02-0012 was studied after a single ex-
travascular (intragastric) administration of the substance 
to rabbits at a dose of 10 mg/kg. The substance is found 
unchanged in urine in trace amounts (0.7% of the dose). 
Thus, nonrenal clearance is typical of ZC02-0012. With 
feces, ZC02-0012 is excreted mainly in the period of 8-24 
hours. The total amount of ZC02-0012 in the faeces col-
lected over 24 h is about 3.5 % of the administered dose. 
Taking into account the results obtained, it is obvious that 
most of the drug undergoes biotransformation in the liver 
and is excreted as metabolites.
Table 9. Results of the Elevated Plus-maze Test in Intragastric Administration of the Test Substances, Me [Q1; Q3].
Test criteria Administered substances and doses Р value
PEG-400 
n=15
ZC02-0012 0.46 
mg/kg 
n=15
ZC02-0012 1.38 
mg/kg 
n=15
ZC02-0012 4.15 
mg/kg 
n=15
Ketorol 1.6 mg/kg 
n=15
Time spent in closed 
arms (sec)
248.95 
[234.57; 270.91]
262.27 
[248.98; 279.31]
253.86 
[241.49; 276.38]
253.31 
[246.58; 268.86]
259.99 
[250.43; 263.56]
0.546
Time spent in open 
arms(sec)
42.84 
[22.29; 58.02]
30.06 
[18.75; 46.91]
38.43 
[16.59; 52.05]
39.3 
[25.44; 47.05]
36.79 
[31.64; 42.99]
0.610
Number of open arm 
entries
2 
[1; 3]
3 
[2; 3]
2 
[1; 2]
2 
[1; 2]
2 
[2; 3]
0.082
Number of closed arm 
entries
4 
[3; 5]
3 
[3; 4]
5 
[3; 5]
4 
[3; 4]
4 
[3; 4]
0.194
Total duration of 
grooming
16.25 
[11.22; 20.1]
16.12 
[13.98; 19.13]
14.49 
[11.34; 19.9]
17.5 
[11.84; 22.21]
12.23 
[10.2; 18.77]
0.487
Number of hangings 
from the open arms
5 
[4; 7]
5 
[3; 7]
6 
[5; 6]
5 
[4; 7]
5 
[4; 7]
0.5
Number of defecations 1 
[0; 2]
1 
[0; 3]
2 
[0; 3]
2 
[0; 3]
2 
[0; 3]
0.823
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Conclusion
1. The substance under laboratory code ZC02-0012 from 
the group of substituted pyrazinopyrimidinones in vitro 
had the most pronounced inhibitory activity against the 
TRPA1 ion channel at a concentration of 91.3 nmol, as its 
full inhibitor.
2. The results of the study of acute toxicity of the se-
lective inhibitor of TRPA1 ion channel, substances under 
code ZC02-0012, showed that the maximum possible 
dose for intragastric administration to mice of 5000 mg/
kg no animal deaths were recorded within two weeks after 
acute priming. The results of keeping watch over the ex-
perimental animals in the intoxication period, when stu-
dying acute toxicity, make it possible to attribute the test 
substance of the selective inhibitor of TRPA1 ion channel, 
ZC02-0012, to the V drug class
3. Selective inhibitor of TRPA1 ion channel, substan-
ce under code ZC02-0012, has an analgesic effect, su-
perior to that of the reference drug Ketorolac, having 
the greatest analgesic activity in the group of NSAIDs, 
comparable with opioid analgesics, according to some 
sources. Analgesic effect was manifested in an increased 
latent period of white laboratory mice staying on the 
plate heated to 55º in the hot plate test and a decreased 
number of writhes in response to intraperitoneal admi-
nistration of a dilute solution of acetic acid to the inbred 
laboratory rats.
4. Selective inhibitor of TRPA1 ion channel, substan-
ce under code ZC02-0012, has an anti-inflammatory ac-
tivity comparable in intensity to Diclofenac sodium, a 
drug with the greatest anti-inflammatory activity in the 
NSAID group. The anti-inflammatory effect was ma-
nifested in the suppression of the hind paw edema of 
the mouse in response to the subaponeurotic injection 
of 2% formaldehyde solution after the administration of 
the test substances.
5. There was neither analgesic nor anti-inflammatory 
activity of the selective inhibitor of TRPA1 ion channel, 
substance under code ZC02-0012, at the dose of 1 mg/kg, 
and it was maximally expressed at the dose of 3 mg/kg. At 
the same time, there was no significant difference in the 
severity of the effects between the doses of 3 mg/kg and 
9 mg/kg, which evidences the absence of a pronounced 
dose-dependent action of the selective inhibitor of TRPA1 
ion channel, substance under code ZC02-0012.
6. Selective inhibitor of TRPA1 ion channel, substance 
under code ZC02-0012, according to the results of beha-
vioral tests – open field test and elevated plus-maze test – 
has no effect on the general locomotor activity levels and 
the anxiety of the laboratory animals.
7. The bioavailability of the selective inhibitor of 
TRPA1 ion channel, substance under code ZC02-0012, 
in inintragastric administration is relatively low, whereas 
ZC02-0012 is intensely distributed into organs and tissues 
with a high level of blood circulation. The highest con-
centration of ZC02-0012 is typical of liver, kidney and 
lungs, the lowest is of muscle tissue. Most of the substan-
ce undergoes rapid biotransformation and is excreted as 
metabolites.
Table 11. Concentration of ZC02-0012 in Blood Plasma of Rabbits after a Single Intravenous Injection at a Dose of 10 mg/kg.
Statistical values
Concentration of ZC02-0012, µg/ml
Time point, min
0 5 10 30 45 60 90 120 180 240
Mean 0.00 0.47 0.28 0.18 0.13 0.07 0.00 0.00 0.00 0.00
SD 0.00 0.10 0.03 0.04 0.08 0.01 0.00 0.00 0.00 0.00
Median 0.00 0.48 0.27 0.19 0.11 0.07 0.00 0.00 0.00 0.00
CV, % - 21.97 11.29 21.48 58.68 14.38 - - - -
Table 12. Concentration of ZC02-0012 in Blood Plasma of Rabbits after a Single Extravascular Administration at a Dose of 10 mg/kg.
Statistical values
Concentration of ZC02-0012, µg/ml
Time point, min
0 5 10 30 45 60 90 120 180 240
Mean 0.00 0.10 0.15 0.08 0.06 0.05 0.00 0.00 0.00 0.00
SD 0.00 0.04 0.03 0.02 0.01 0.00 0.00 0.00 0.00 0.00
Median 0.00 0.08 0.14 0.07 0.06 0.05 0.00 0.00 0.00 0.00
CV, % - 38.76 19.47 24.96 12.68 9.77 - - - -
Figure 4. Averaged pharmacokinetic curves of ZC02-0012 in 
blood plasma of rabbits after a single administration.
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